Showing results (101-110 of 183) with videos related to
Sort By:
Pageof 19
Journal of Acquired Immune Deficiency Syndromes (1999)|October 5, 2013
Peak bone mass in young HIV-infected patients compared with healthy controlsEugènia Negredo, Pere Domingo, Elena Ferrer, et al.The Journal of Antimicrobial Chemotherapy|December 25, 2014
Atherogenic properties of lipoproteins in HIV patients starting atazanavir/ritonavir or darunavir/ritonavir: a substudy of the ATADAR randomized studyMaria Saumoy, Jordi Ordóñez-Llanos, Esteban Martínez, et al.The Journal of Antimicrobial Chemotherapy|June 26, 2012
Simplification to dual antiretroviral therapy including a ritonavir-boosted protease inhibitor in treatment-experienced HIV-1-infected patientsJoaquin Burgos, Manuel Crespo, Vicenç Falcó, et al.The Journal of Antimicrobial Chemotherapy|January 23, 2015
Antiviral activity and CSF concentrations of 600/100 mg of darunavir/ritonavir once daily in HIV-1 patients with plasma viral suppressionMaria S Di Yacovo, José Moltó, Elena Ferrer, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|November 29, 2012
Maraviroc once-daily nucleoside analog-sparing regimen in treatment-naive patients: randomized, open-label pilot studyAnthony Mills, Donna Mildvan, Daniel Podzamczer, et al.Lancet (London, England)|January 12, 2013
Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 studyFrancois Raffi, Anita Rachlis, Hans-Jürgen Stellbrink, et al.Plos One|August 21, 2020
Lipids, biomarkers, and subclinical atherosclerosis in treatment-naive HIV patients starting or not starting antiretroviral therapy: Comparison with a healthy control group in a 2-year prospective studySilvana Di Yacovo, Maria Saumoy, José Luís Sánchez-Quesada, et al.AIDS (London, England)|March 28, 2003
Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral loadJuan A Arnaiz, Josep Mallolas, Daniel Podzamczer, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 22, 2021
Total and Unbound Doravirine Concentrations and Viral Suppression in CSFJuan Tiraboschi, Sofia Scévola, Sujan Dilly Penchala, et al.Plos One|January 31, 2019
Re-boost immunizations with the peptide-based therapeutic HIV vaccine, Vacc-4x, restores geometric mean viral load set-point during treatment interruptionJürgen K Rockstroh, David Asmuth, Giuseppe Pantaleo, et al.Pageof 19